The primary gene alteration here - activation of JAK3 via a recurrent mutation JAK3 (V722I) - was previously reported in a variety of hematopoietic neoplasms as a driver mutation enabling factor-independent growth [10]. Here, JAK3 is linked to hematopoietic and lymphoid cell neoplasm.